COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01748708
Recruitment Status : Withdrawn (The protocol has undergone significant changes and the investigator feels that it is reasonable to submit a new protocol for review and approval.)
First Posted : December 12, 2012
Last Update Posted : November 20, 2017
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Z. J. Daskalakis, Centre for Addiction and Mental Health

Brief Summary:
Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression that is resistant to common modalities of treatment, such as antidepressant medication. Although treatment with ECT has benefited many individuals with treatment resistant depression (rates as high as 50-75%), its more widespread use is hindered by the social stigma associated with the treatment, as well as by its significant cognitive side effects. Moreover, ECT cannot be precisely targeted, since it produces a widespread activation of the brain surface, in turn, affecting many different functional areas. Magnetic seizure therapy (MST) is currently being investigated as an alternative to ECT, as it is more focused to one area of the brain. Rather than applying electrical stimuli to induce a seizure, as is done in ECT, MST uses repetitive magnetic stimulation to produce the seizure. Preliminary research suggests that MST can result in therapeutic effects comparable to those produced by ECT, but without the negative side effects on cognition. The proposed study is a randomized, controlled trial, in which the efficacy and side effect profile of MST will be compared to those of ECT. If successful, the results of this study may lead to increased treatment availability and accessibility, as well as lessen the substantial health care costs associated with treatment resistant depression.

Condition or disease Intervention/treatment Phase
Depressive Disorder Device: Magnetic seizure therapy Device: Electroconvulsive therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.
Actual Study Start Date : December 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures

Arm Intervention/treatment
Experimental: Magnetic seizure therapy Device: Magnetic seizure therapy
100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
Other Name: MagPro MST (Tonica Elektronik A/S, Denmark)

Active Comparator: Electroconvulsive therapy Device: Electroconvulsive therapy
ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
Other Name: MECTA spECTrum 5000Q

Primary Outcome Measures :
  1. Hamilton Rating Scale for Depression, 24-item (HRSD-24) [ Time Frame: Change from baseline in HRSD-24 score at date of symptom remission or date of the 15th treatment, whichever comes first, assessed up to 6 months. ]
    The HRSD-24 is a semi-structured, clinician-administered scale used to assessed the severity of depressive symptoms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • inpatients or outpatients
  • voluntary and competent to consent to treatment
  • DSM-IV diagnosis of major depressive disorder, single or recurrent, without psychotic features
  • have failed to achieve a clinical response to adequate treatment trials of at least two antidepressants (with adequacy established according to a predefined criterion on the Antidepressant Treatment History Form (ATHF)) or have been unable to tolerate at least two antidepressants
  • have a baseline HRSD-24 score ≥ 21
  • are considered to be appropriate to receive ECT as assessed by an ECT attending psychiatrist and an anaesthesiologist
  • are agreeable to keeping their current antidepressant treatment constant through the duration of the study
  • are able to adhere to the intervention schedule
  • meet the MST safety criteria
  • are on a medically acceptable form of birth control if a woman of child-bearing potential
  • are a resident of Canada

Exclusion Criteria:

  • have a history of DSM-IV substance dependence or abuse within the past three months
  • have a concomitant major unstable medical illness
  • are acutely suicidal with imminent intent
  • are pregnant or intend to get pregnant during the study
  • have a DSM-IV confirmed diagnosis of bipolar disorder, any psychotic disorder, obsessive compulsive disorder, or post-traumatic stress disorder (current or within the last year)
  • have a DSM-IV diagnosis of borderline personality disorder as assessed by a study investigator
  • have possible or probable dementia
  • have failed a course of ECT within the current depressive episode
  • have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or cognitive impairment (e.g., a space occupying brain lesion, a history of stroke, a cerebral aneurysm, a seizure disorder, Parkinson's disease, Huntington's chorea, multiple sclerosis, head trauma with loss of consciousness for greater than or equal to five minutes)
  • present with a medical condition, a medication, or a laboratory abnormality that could cause a major depressive episode or significant cognitive impairment in the opinion of the investigator (e.g., hypothyroidism with low TSH, rheumatoid arthritis requiring high dose prednisone, or Cushing's disease)
  • have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
  • require a benzodiazepine with a dose equivalent to lorazepam 2 mg/day or higher or any anticonvulsant due to the potential of these medications to limit the efficacy of both MST and ECT
  • have an inability to communicate in English fluently enough to complete the neuropsychological tests
  • have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01748708

Layout table for location information
Canada, Ontario
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4
Sponsors and Collaborators
Centre for Addiction and Mental Health
Canadian Institutes of Health Research (CIHR)
Layout table for investigator information
Principal Investigator: Z. Jeffrey Daskalakis, MD, PhD. Centre for Addiction and Mental Health

Additional Information:
Layout table for additonal information
Responsible Party: Z. J. Daskalakis, Chair, Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health Identifier: NCT01748708    
Other Study ID Numbers: 080-2012
First Posted: December 12, 2012    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: November 2017
Keywords provided by Z. J. Daskalakis, Centre for Addiction and Mental Health:
Magnetic seizure therapy
Electroconvulsive therapy
Treatment resistant depression
Treatment resistance
Randomized controlled trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms